Cullinan Therapeutics, Inc.
Cullinan Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing potential first- or best-in-class therapies for autoimmune diseases and cancer. The company’s pipeline centers on T cell engager and bispecific antibody programs, with lead assets such as CLN-978 in autoimmune disease and additional partnered or in-licensed programs advancing through clinical development.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueClinical-stage immunology assets aimed at B-cell driven autoimmune diseases, led by CLN-978.
Bispecific and other immuno-oncology candidates targeting solid tumors and hematologic cancers.
Co-development and licensed assets advanced with external partners, including zipalertinib.
Earlier programs and options that expand the pipeline and provide future pipeline optionality.
Customers
Cullinan does not sell approved products today, so its near-term 'customers' are primarily clinical trial participants, investigators, and development partners rather than commercial buyers. If programs are approved, the end customers would be physicians, hospitals, and specialty pharmacies treating autoimmune disease and cancer patients. The company may also rely on third-party collaborators for future commercialization and distribution.
Patients with SLE, RA, Sjögren’s disease, or cancer who enroll in studies to evaluate safety and efficacy.
Hospitals, research centers, and physicians that recruit patients and generate clinical data for the pipeline.
Partners such as Taiho or licensors/collaborators that share development, rights, or commercialization economics.
Specialists, hospitals, and infusion centers that would prescribe or administer approved therapies.
Strategy
Cullinan’s strategy is to build a differentiated pipeline around T cell engagers and bispecific antibodies, first in oncology and now in autoimmune disease. The company is prioritizing clinical proof-of-concept, selective licensing, and partner-enabled development while preserving capital for the most promising assets.
Clinical data in SLE, RA, and Sjögren’s disease is central to validating the platform outside oncology.
External assets can add therapeutic breadth without relying only on internal discovery.
Partnered programs can share development burden and create optionality for future value creation.
Geography
Cullinan is headquartered in Cambridge, Massachusetts and operates as a U.S.-based clinical-stage biotech with global development reach. Its lead autoimmune studies are global, while the RA study for CLN-978 is ongoing in Europe, and the company also holds rights outside greater China for some assets. Geography matters mainly through trial execution, regulatory pathways, and partner rights rather than current product sales.
Risks
Cullinan is exposed to the high failure rate of clinical-stage biotech, where safety or efficacy setbacks can halt programs before approval. It also depends on external capital, third-party CROs, and future partnerships, so delays, funding pressure, or weak trial execution could materially slow development. Commercialization risk remains high because the company has no approved products, no sales infrastructure, and faces intense competition from better-funded pharma and biotech peers.
- Clinical development failureImpact: CriticalLikelihood: Medium
Lead assets are still in early clinical testing and may not demonstrate acceptable safety or efficacy.
Exposure: CLN-978 and other pipeline programs
- Capital dependence and dilutionImpact: HighLikelihood: High
The company has a history of operating losses and negative cash flow and may need additional financing.
Exposure: All development programs
- Regulatory and approval delaysImpact: HighLikelihood: Medium
FDA review timing and clinical/regulatory milestones can be delayed, especially for new submissions.
Exposure: Zipalertinib NDA timing and future filings
- Competition for patients, sites, and talentImpact: MediumLikelihood: Medium
Larger companies can outspend Cullinan in recruiting patients, investigators, and scientific staff.
Exposure: Clinical trial execution
Accounting
Judgemental itemsTrial and manufacturing costs are estimated before invoices are finalized, affecting expense timing.
Impact: Can shift quarterly R&D expense and liabilities
License agreements may require future payments upon clinical, regulatory, or sales milestones.
Impact: Potential future cash outflows not yet recognized as liabilities
Office and facility leases create recognized right-of-use assets and lease liabilities.
Impact: Affects leverage and future cash commitments
A large portion of operating expense is non-cash stock compensation for employees.
Impact: Reduces comparability of GAAP losses to cash burn
Similar listed companies
Publicly listed companies with a comparable business focus.
Monopar Therapeutics
MNPR · Pharmaceutical Preparations
Monopar Therapeutics is a U.S.-based clinical-stage biopharmaceutical company developing drug candidates for Wilson disease and advanced cancers.
Xilio Therapeutics, Inc.
XLO · Pharmaceutical Preparations
Xilio Therapeutics is a U.S.-based biotechnology company focused on developing tumor-activated immunotherapies for cancer.
Climb Bio, Inc.
CLYM · Pharmaceutical Preparations
Allogene Therapeutics, Inc.
ALLO · Biological Products, (No Diagnostic Substances)
Allogene Therapeutics is a clinical-stage immuno-oncology company developing genetically engineered allogeneic T cell therapies for cancer and autoimmune disease.
Compass Therapeutics, Inc.
CMPX · Biological Products, (No Diagnostic Substances)
Compass Therapeutics is a clinical-stage biopharmaceutical company focused on developing antibody-based cancer therapies.
Cabaletta Bio, Inc.
CABA · Biological Products, (No Diagnostic Substances)
Last updated: 24/09/2026